Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6UX65

UPID:
DRAM2_HUMAN

ALTERNATIVE NAMES:
Transmembrane protein 77

ALTERNATIVE UPACC:
Q6UX65; B3SUG9; Q4VWF6; Q86VD3; Q8NBQ4

BACKGROUND:
The protein DNA damage-regulated autophagy modulator protein 2, with its alternative name Transmembrane protein 77, is instrumental in autophagy initiation and plays a vital role in the retina's photoreceptor cells' renewal. Its ability to induce apoptosis when combined with DRAM1 highlights its potential in cellular regulation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of DNA damage-regulated autophagy modulator protein 2 could open doors to potential therapeutic strategies for combating Cone-rod dystrophy 21, characterized by rapid vision deterioration.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.